Efficacy and safety of cannabis for treating children with refractory epilepsy
Michelle Neale Children’s nurse, Chailey Heritage School, Lewes, East Sussex, England
The aim of this literature review was to examine the evidence base for the safety and efficacy of cannabis in treating children with refractory epilepsy.
Clinical and medical databases were searched and four articles were included in the final analysis, which included retrospective reviews and open-label trials with a total sample size of 424. One clinical trial included administration of cannabidiol, the non-psychoactive compound of cannabis, while the other three articles stated that the compound administered to participants contained tetrahydrocannabidiol, the psychoactive constituent of cannabis.
Cannabis may reduce seizures in some children and young people with refractory epilepsy, however, its success may be affected by aetiology of the epilepsy or concomitant anti-epileptic drug use, and a therapeutic dose has not been found. Positive side effects were also found including improved sleep, alertness and mood. More research is needed on this subject, including randomised controlled trials. Nurses who are aware of patients and families wishing to trial cannabis for refractory epilepsy should have full and frank discussions.
Nursing Children and Young People. 29, 7, 32-37. doi: 10.7748/ncyp.2017.e907Correspondence
This article has been subject to open peer review and has been checked for plagiarism using automated softwareConflict of interest
Received: 05 February 2017
Accepted: 31 March 2017
Want to read more?
Subscribe for unlimited access
Try 1 month’s access for just £1 and get:
- Full access to the website and the online archive
- Bi-monthly digital edition
- RCNi Portfolio and interactive CPD quizzes
- RCNi Learning with 200+ evidence-based modules
- 10 articles a month from any other RCNi journal
Already subscribed? Log in
Alternatively, you can purchase access to this article for the next seven days. Buy now